Cyclosporiasis cases reported in the US in 2026?
Short Answer
Both the model and the market overwhelmingly agree that cyclosporiasis cases reported in the US in 2026 will be Above 4k, with only minor residual uncertainty. National health agencies have reported over 18,000 combined confirmed and suspected cases as of late July 2026.
1. Executive Verdict
- Over 18,000 total cyclosporiasis cases already reported make higher thresholds highly probable.
- A six-week reporting lag and five remaining months suggest 20,000 total cases are likely.
Who Wins and Why
| Outcome | Market | Model | Why |
|---|---|---|---|
| Above 20k | 44.0% | 54.5% | Over 18,000 cases are reported by late July, with a typical lag and remaining months. |
| Above 14k | 86.0% | 89.9% | Over 18,000 cases have already been reported nationally by late July 2026. |
| Above 10k | 90.0% | 95.0% | Over 18,000 cases have already been reported nationally by late July 2026. |
| Above 16k | 80.0% | 85.3% | Over 18,000 cases have already been reported nationally by late July 2026. |
| Above 8k | 91.0% | 95.0% | Over 18,000 cases have already been reported nationally by late July 2026. |
Current Context
Nationally, cyclosporiasis cases top 18,000 with ongoing outbreaks. As of July 30, 2026, the CDC has reported 6,707 laboratory-confirmed domestically acquired cyclosporiasis cases since May 1, 2026. An additional 11,500+ suspected cases remain under investigation, bringing the national total to over 18,000 [^][^]. One major multistate outbreak involves 1,947 cases linked to contaminated iceberg lettuce from Taylor Farms across nine states. Federal officials are also investigating other unrelated cyclosporiasis clusters in 41–45 states [^][^]. Case counts are expected to continue rising due to a typical six-week reporting lag between illness onset and surveillance notification [^][^].
US public health infrastructure faces stability challenges in 2026. The 2026 public health landscape in the U.S. involves intense debate over federal institutional stability. This follows significant workforce reductions at the CDC and FDA, alongside new administrative policies restricting certain life sciences research, such as dangerous gain-of-function studies, effective mid-November 2026 [^][^][^].
2. Market Behavior & Price Dynamics
Historical Price (Probability)
Outcome probability
Date
To: Desk
From: Quant
Re: Market Analysis: KXCYCLOCOUNT-27JAN01-A4000
The contract for 2026 US cyclosporiasis cases has traded in a tight, high-conviction band between 79.0% and 99.0%. The market opened at 97.0% and has maintained a sideways trend, currently priced at 96.0%. This price action indicates that participants have consistently viewed a high case count as the probable outcome. The floor of the range appears to be around 80%, with a clear ceiling at 99.0%. The primary price activity has been consolidating in the 90-99% range, treating this as a stable level of conviction.
A notable price movement occurred on July 22, when the probability spiked 14.0 percentage points from 85.0% to 99.0%. This move was not driven by a specific data release but rather by market anticipation of an escalating outbreak. This sentiment was later validated by a July 30 CDC report, which detailed 6,707 laboratory-confirmed cases since May 1 and noted that the total number of confirmed and suspected cases exceeded 18,000. The report also identified a significant multistate outbreak linked to Taylor Farms lettuce, alongside other clusters across 41-45 states.
Total volume stands at 1,196 contracts. Sample data points show zero volume on several days, which suggests trading is sporadic and likely concentrated around key news events or shifts in public awareness. The combination of low-volume trading days and a stable, high price suggests strong conviction among contract holders. The market has effectively priced in a high probability of the event resolving to YES and is now in a holding pattern, awaiting final confirmation.
3. Significant Price Movements
Notable price changes detected in the chart, along with research into what caused each movement.
Outcome: Above 18k
📈 July 30, 2026: 8.0pp spike
Price increased from 46.0% to 54.0%
What happened: The primary driver for the 8.0 percentage point spike on July 30, 2026, was breaking news from traditional media outlets confirming that the suspected total of cyclosporiasis cases in the US had surpassed the 18,000 threshold. As of that date, public health reports and news sources like Food Safety News and KTALnews.com announced that total suspected cases exceeded 18,200, with some reports indicating the patient count topped 20,000 nationally [^][^][^]. This direct confirmation of the market's "Above 18k" condition coincided with the price movement. Social media activity was not identified as a primary driver or contributing accelerant in the provided information.
📈 July 23, 2026: 24.0pp spike
Price increased from 25.0% to 49.0%
What happened: The primary driver of the prediction market price spike was the emergence of news and official data indicating that the total number of cyclosporiasis cases in the US had surpassed 18,000. By late July 2026, the CDC reported 6,707 laboratory-confirmed cases and was actively monitoring more than 11,500 additional cases, totaling over 18,200 identified patients [^][^][^]. This official information, corroborated by news headlines like "Over 18K cyclosporiasis cases now suspected in US" [^], directly signaled the "Above 18k" outcome. Based on the provided sources, social media activity was irrelevant as no related posts or viral narratives were identified.
Outcome: Above 16k
📈 July 29, 2026: 24.0pp spike
Price increased from 56.0% to 80.0%
What happened: The primary driver of the 24.0 percentage point price spike was the rapid escalation and reporting of cyclosporiasis cases on July 29, 2026. News outlets announced that the total patient count, encompassing both confirmed and suspected cases, had exceeded 20,000, significantly surpassing the "Above 16k" market outcome [^][^]. This widespread reporting likely coincided with and was amplified by social media and news analysis discourse that focused on the outbreak's rapid acceleration and the 16k threshold, contributing to the market's rapid repricing [^]. Social media was a contributing accelerant, ensuring the rapid dissemination and discussion of these escalating figures.
📉 July 19, 2026: 15.0pp drop
Price decreased from 35.0% to 20.0%
What happened: The market for "Above 16k" cyclosporiasis cases saw a 15.0 percentage point drop on July 19, 2026. However, available web research from late July 2026 reports a rapidly escalating U.S. outbreak, with over 20,000 total patients identified by July 30, 2026, including over 18,200 suspected cases [^][^]. This post-movement information suggests the probability of exceeding 16,000 cases should have been high, or increasing, around July 19, 2026. No social media activity or traditional news on or before July 19, 2026, that would cause a drop in market confidence for "Above 16k" is present in the provided sources. Therefore, based on the available information, the primary driver for this specific price movement cannot be identified, as the provided context suggests the opposite trend.
Outcome: Above 14k
📈 July 22, 2026: 46.0pp spike
Price increased from 36.0% to 82.0%
What happened: The 46.0 percentage point spike on July 22, 2026, was primarily driven by increasing awareness and anticipation of a rapidly escalating cyclosporiasis outbreak in the US. While specific official reports confirming cases above 14,000 were not released until shortly after the market movement, by July 27, 2026, the CDC reported 6,707 laboratory-confirmed cases and over 11,500 additional cases under investigation, totaling more than 18,207 potential cases [^]. Michigan alone reported over 10,000 cases by late July, reinforcing the likelihood of the "Above 14k" outcome [^]. No specific social media activity from key figures or viral narratives appeared to be a primary driver or contributing accelerant based on the provided information.
4. Market Data
Contract Snapshot
A "YES" contract resolves if the total number of Cyclosporiasis cases reported in the US for the year 2026 is above the specified threshold (e.g., 18,000 for an "Above 18k" contract); a "NO" contract resolves if the count is at or below that threshold. The market will settle by the maximum payout date of January 1, 2027. The provided content does not detail any special settlement conditions, specific data sources, or rounding rules.
Available Contracts
Market options and current pricing
| Outcome bucket | Yes (price) | No (price) | Last trade probability |
|---|---|---|---|
| Above 4k | $1.00 | $0.01 | 96% |
| Above 6k | $0.99 | $0.06 | 94% |
| Above 12k | $0.97 | $0.06 | 93% |
| Above 8k | $0.99 | $0.07 | 91% |
| Above 10k | $0.99 | $0.07 | 90% |
| Above 14k | $0.84 | $0.22 | 86% |
| Above 16k | $0.79 | $0.23 | 80% |
| Above 18k | $0.54 | $0.53 | 54% |
| Above 20k | $0.44 | $0.60 | 44% |
Market Discussion
As of July 30, 2026, the CDC reported 6,707 laboratory-confirmed domestically acquired cyclosporiasis cases since May 1, 2026, and was monitoring over 11,500 suspected cases, while media reports estimated over 18,000 to 20,000 suspected or confirmed cases across 45 states as of late July 2026 [^][^][^]. A major multistate outbreak associated with iceberg lettuce served at Taco Bell restaurants was identified, involving at least 1,947 confirmed cases across nine states as of July 24, 2026 [^][^]. The 2026 outbreak also became a subject of activity on prediction markets, with traders tracking rising national case counts throughout July [^][^].
5. How does the CDC's historical data on reporting lags project the final 2026 cyclosporiasis case count based on the mid-year figures?
| Reporting Lag | approximately 6-week [^][^][^] |
|---|---|
| Confirmed Cases (late July 2026) | 4,173 [^][^][^] |
| Suspect Cases Under Investigation | 7,400 [^][^][^] |
Cyclosporiasis cases are significantly underreported due to reporting lags. The Centers for Disease Control and Prevention (CDC) estimates an approximate six-week reporting lag for cyclosporiasis cases, indicating that current mid-year figures substantially underrepresent final annual totals [^][^][^]. As of late July 2026, 4,173 laboratory-confirmed domestically acquired cases have been reported, with an additional 7,400 or more suspect cases currently under investigation [^][^][^]. This lag effect means that the full scope of an outbreak is not immediately apparent in real-time data.
Final 2026 cyclosporiasis case counts are projected to be high. Final annual cyclosporiasis case counts are routinely revised retroactively, often because of voluntary reporting mechanisms in many jurisdictions, which contributes to systematic undercounting and reliance on preliminary, changeable data [^][^][^][^][^]. Analysts predict that 2026 is likely to become the worst year on record for cyclosporiasis, potentially surpassing the 2019 peak of 4,703 cases, considering the current large-scale multistate outbreak and the substantial number of pending investigations [^]. However, the available research does not provide a specific quantitative method or a direct projection for the final 2026 case count, derived from historical reporting lag data and the current mid-year figures.
6. What are the primary risk factors and potential new outbreak sources for the remainder of 2026 that could influence the final CDC cyclosporiasis case count?
| Confirmed Cases | 6,707 (as of July 30, 2026) [^][^] |
|---|---|
| Potential Cases Under Investigation | Over 11,500 (nationwide) [^][^] |
| Primary Risk Factors | Climate-driven extreme heat and drought, complex produce supply chains [^][^] |
Climate change and complex supply chains drive cyclosporiasis risk. Primary risk factors for cyclosporiasis outbreaks for the remainder of 2026 include climate-driven extreme heat and drought, which elevate the risk of contaminated irrigation water, alongside the complexity of national produce supply chains [^][^]. Potential new outbreak sources are predominantly linked to foodborne transmission, frequently involving produce, with many patterns remaining unidentified or spanning multiple states, contributing to the ongoing surge in cases [^]. Federal health officials are actively investigating several multistate cyclosporiasis outbreaks, with evidence pointing to lettuce, specifically from Taylor Farms, as a potential source for at least one outbreak affecting Michigan, Ohio, Kentucky, and West Virginia [^][^].
Cyclosporiasis cases are surging amid significant surveillance challenges. As of July 30, 2026, the CDC has officially reported 6,707 laboratory-confirmed domestically acquired cases of cyclosporiasis since May 1, 2026, and is investigating over 11,500 additional potential cases nationwide [^][^]. Structural challenges impacting surveillance include reduced federal staffing for food safety investigations and the shift to optional reporting for Cyclospora, which has diminished the ability to identify outbreak sources promptly [^][^]. Consequently, state-reported data, which often includes probable cases, may significantly exceed official CDC confirmed counts [^][^].
7. How does the 2026 multistate outbreak compare to major outbreaks in previous years, such as 2018, in terms of case count trajectory and geographic spread?
| Confirmed Cases (2026) | 6,707 (as of July 28, 2026) [^] |
|---|---|
| Additional Cases Under Investigation | Over 11,500 [^] |
| Total States Affected | At least 45 states [^] |
The 2026 cyclosporiasis outbreak is the largest in U.S. history. It significantly surpasses major outbreaks from previous years, including 2018 and 2019. As of July 28, 2026, the CDC has reported 6,707 laboratory-confirmed domestic cases since May 1, 2026. Additionally, over 11,500 further cases are currently under investigation, underscoring the event's extensive scale [^].
This outbreak features a uniquely steep trajectory and broad geographic spread. A notable 6-week lag has been observed between the onset of illness and its confirmation by the CDC. While the primary cluster linked to lettuce affected at least 9 states, the overall spread of cases has been reported across at least 45 states. Prediction markets are tracking the total 2026 U.S. cyclosporiasis case count, with some projections reaching as high as 16,000 confirmed cases [^].
8. What is the CDC's official methodology and publication schedule for finalizing and releasing the national cyclosporiasis surveillance data for the 2026 calendar year?
| Data Status (2026 calendar year) | Provisional (subject to change) [^][^] |
|---|---|
| Finalization Timeline | Approximately 10 months after end of calendar year [^][^] |
| Initial Publication Type | MMWR Early Release Table [^][^] |
National cyclosporiasis data remains provisional before finalization. The Centers for Disease Control and Prevention (CDC) considers national cyclosporiasis surveillance data, including for the 2026 calendar year, to be provisional throughout its initial reporting period. This data is subject to change as reconciliation efforts are completed with state and territorial partners [^][^]. Finalized data for a given year is typically completed approximately 10 months after the conclusion of that calendar year [^][^].
Finalized data sees two distinct MMWR publications. The initial publication of this finalized information occurs in an MMWR Early Release Table, which is often titled "Notice to Readers: Final [YYYY] Reports of Nationally Notifiable Infectious Diseases" [^][^]. Following this initial release, the finalized 2026 data will subsequently be incorporated into the annual MMWR Summary of Notifiable Infectious Diseases and Conditions--United States. This comprehensive summary typically appears about one year after the initial Early Release Table publication [^][^].
9. How might the 2026 workforce reductions at the CDC and FDA impact the speed and accuracy of cyclosporiasis case investigation and reporting?
| CDC Workforce Reduction | Approximately 25% (2025-2026) [^][^][^][^] |
|---|---|
| FDA Workforce Reduction | Approximately 20% (2025-2026) [^][^][^][^] |
| 2026 Cyclosporiasis Outbreak Cases | Over 4,100 laboratory-confirmed [^][^][^][^] |
Workforce reductions significantly hampered public health surveillance, slowing cyclosporiasis outbreak investigation and reporting. Reductions of approximately 25% at the CDC and 20% at the FDA for 2025-2026 have severely compromised public health surveillance capabilities, including the capacity to investigate and respond to outbreaks such as the 2026 cyclosporiasis outbreak [^][^][^][^]. These cutbacks have directly led to slower outbreak investigations, causing delays in data analysis, pathogen monitoring, and communication with healthcare providers, thereby compromising the speed and accuracy of case investigation and reporting [^][^].
Staff cuts weakened specialized teams and FoodNet removal impeded comprehensive surveillance. A notable consequence of these staff reductions at the CDC is the significant weakening of specialized teams, such as the food parasite tracking team, which was reduced from 11 scientists to just three [^][^]. This diminishment directly contributes to delays in data analysis, pathogen monitoring, and communications with healthcare providers, affecting the timeliness and effectiveness of outbreak investigations and reporting. Further compounding the issue, the removal of cyclosporiasis from FoodNet surveillance, effective July 1, 2025, has impeded the ability to track long-term trends and ascertain the full scale of outbreaks [^][^][^]. Despite ongoing separate outbreak-specific investigation programs [^][^], this reduced surveillance capacity has impacted the comprehensive understanding and accuracy of reported case counts during the major cyclosporiasis outbreak in late July 2026, which currently reports over 4,100 laboratory-confirmed domestic cases by the CDC and has thousands more under investigation [^][^][^][^].
10. What Could Change the Odds
Key Catalysts
As of July 28, 2026, the CDC confirmed 6,707 laboratory-confirmed domestically acquired cyclosporiasis cases since May 1, 2026. Health authorities are investigating over 11,500 suspected or non-confirmed cases, bringing the total suspected cases to over 18,000 [^][^]. This outbreak is linked to contaminated iceberg lettuce sourced from Mexico, affecting nine states including Illinois, Indiana, Kansas, Kentucky, Michigan, Ohio, Oklahoma, Pennsylvania, and West Virginia, with Michigan and Ohio reporting the highest case counts [^][^][^].
Prediction markets like Polymarket, Kalshi, and Parity have established binary contracts tied to the 2026 cyclosporiasis surge. These markets focus on thresholds for confirmed cases by July 31, 2026, with targets ranging from 1,800 to over 10,000 cases [^][^][^][^]. Public health surveillance data directly drives financial settlements in these markets [^][^][^][^]. Additionally, participants are betting on whether confirmed cases will spread across all 48 contiguous U.S. states by August 31, 2026, creating a secondary timeline of focus for traders [^].
Key Dates & Catalysts
- Expiration: January 08, 2027
- Closes: January 01, 2027
11. Decision-Flipping Events
- Trigger: As of July 28, 2026, the CDC confirmed 6,707 laboratory-confirmed domestically acquired cyclosporiasis cases since May 1, 2026.
- Trigger: Health authorities are investigating over 11,500 suspected or non-confirmed cases, bringing the total suspected cases to over 18,000 [^] [^] .
- Trigger: This outbreak is linked to contaminated iceberg lettuce sourced from Mexico, affecting nine states including Illinois, Indiana, Kansas, Kentucky, Michigan, Ohio, Oklahoma, Pennsylvania, and West Virginia, with Michigan and Ohio reporting the highest case counts [^] [^] [^] .
- Trigger: Prediction markets like Polymarket, Kalshi, and Parity have established binary contracts tied to the 2026 cyclosporiasis surge.
13. Historical Resolutions
No historical resolution data available for this series.
